Immutep to Present Pivotal Lung Cancer Trial at ELCC 2025

Immutep Ltd ( (AU:IMM) ) has provided an update.

Immutep Limited announced a poster presentation for its pivotal TACTI-004 Phase III trial at the European Lung Cancer Congress 2025. The trial evaluates the combination of Immutep’s eftilagimod alfa with KEYTRUDA and chemotherapy for advanced non-small cell lung cancer. This global trial, enrolling 750 patients across 25 countries, aims to potentially shift treatment paradigms for this cancer type, irrespective of PD-L1 expression, and confirms the promising safety and efficacy of the treatment.

More about Immutep Ltd

Immutep Limited is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the field of Lymphocyte Activation Gene-3 (LAG-3) therapeutics, aiming to either stimulate or suppress the immune response. Immutep’s diverse product portfolio is designed to offer innovative treatment options to patients and maximize shareholder value.

YTD Price Performance: -9.09%

Average Trading Volume: 5,000

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $273.1M

For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.